Physician profile
Karl Peter Uy
NPI 1205064219
$474.16
in general payments reported to CMS, 2019-2025
11 companies · $91.65 in 2025
The $91.65 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.57 · 2020: $73.79 · 2021: $16.30 · 2022: $64.26 · 2023: $116 · 2024: $28.89 · 2025: $91.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $236.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $83.34 | 2022-2024 | Mounjaro |
| Pfizer INC. | $75.01 | 2020-2021 | |
| Amgen INC. | $53.06 | 2022-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $47.46 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $47.14 | 2022-2023 | Farxiga |
| Abbvie INC. | $44.19 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $34.12 | 2019 | |
| Novo Nordisk INC | $31.12 | 2019 | |
| Irhythm Technologies, INC. | $25.31 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $18.33 | 2019 | |
| Eisai INC. | $15.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Peter Uy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.